We are a clinical-stage biopharmaceutical company developing oral fixed-dose combination therapies and psychedelic-assisted treatments for serious chronic conditions. Our principal development priority is IHL-42X for obstructive sleep apnea. We are also evaluating the next clinical development plan for PSX-001 in generalized anxiety disorder and the potential for further development of IHL-675A in inflammatory conditions.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Completed Phase 2 RePOSA program; FDA Fast Track designation; DReAMzz Phase 2 dose-optimization study underway ahead of a planned Phase 3 registration program; 505(b)(2) pathway planned.
PSX-001
Phase 2 · ActiveModality: small molecule (oral psilocybin, dosed with psychological support)
Target serotonin receptors
Indications
Generalized anxiety disorder (GAD)(Phase 2)
Status note Completed PsiGAD1 proof-of-concept trial; FDA IND cleared for PsiGAD2 Phase 2b dose-comparison study in the U.S. and U.K. Company also holds a 50% JV (Mind Medicine Australia) operating a psychedelic-assisted therapies services clinic.
Status note Australian Phase 2 RA trial terminated due to patient recruitment challenges; company is designing an IND-opening study for RA (505(b)(2) pathway proposed).
Per-asset detail extracted from the 10-Q filed 2026-05-15. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.